Screen Readers Skip to Content

Researchers Urge More Transparency From FDA

Synopsis: Researchers create Blueprint for Transparency to advance the development of safe and effective new products.1

Author: Johns Hopkins University Bloomberg School of Public Health Contact:

Published: 2017-03-18

Main Digest

As the new administration considers the future direction of the Food and Drug Administration, a group of leading researchers has created a Blueprint for Transparency at the agency to advance the development of safe and effective new products.

The researchers include senior faculty from the Johns Hopkins Bloomberg School of Public Health, Harvard Medical School/Brigham and Women's Hospital, Yale Medical School, and Yale Law School. The project was organized by Joshua Sharfstein, MD, Professor of the Practice at the Bloomberg School.

Sharfstein and Michael Stebbins, PhD, of the Laura and John Arnold Foundation, have authored an overview of the Blueprint in JAMA, released online March 13.

The full report, Blueprint for Transparency at the U.S. Food and Drug Administration, is being released simultaneously online at

"FDA is more than an agency that makes regulatory decisions," says Sharfstein, a former FDA Principal Deputy Commissioner. "It is also a repository for scientific analysis and data that, if more widely available, would improve understanding of existing therapies, the pharmaceutical pipeline and opportunities for innovative product development."

The report makes 18 recommendations in five principal areas:

All of the Blueprint's recommendations can be implemented by FDA without new legislation from Congress, and all respect legal protections for trade secrets.

"Enhancing Transparency at the U.S. Food and Drug Administration: Moving Beyond the 21st Century Cures Act" was written by Joshua M. Sharfstein and Michael Stebbins. The full Blueprint for Transparency was written by the FDA Transparency Working Group which includes Sharfstein as well as James Dabney Miller, Anna L Davis, Caleb Alexander, Brian Smith and Anam Chaudry of the Bloomberg School; Joseph S. Ross of Yale Medical School; Margaret E. McCarthy of Yale Law School; and Aaron Kesselheim of Brigham and Women's Hospital/Harvard Medical School.

The Blueprint for Transparency is supported by a grant from the Laura and John Arnold Foundation.

Related FDA Approvals Documents

Full List of FDA Approvals Publications

Recent Disability News and Updates

Full List of Disabled World News Updates

Disclaimer: Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Please report outdated or inaccurate information to us.

Disclosure: Disabled World is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Any 3rd party offering or advertising on does not constitute endorsement by Disabled World. View our Advertising Policy for further information.

Cite Page: Journal: Disabled World. Language: English (U.S.). Author: Johns Hopkins University Bloomberg School of Public Health. Electronic Publication Date: 2017-03-18. Title: Researchers Urge More Transparency From FDA, Source: <a href=>Researchers Urge More Transparency From FDA</a>. Retrieved 2021-03-07, from - Reference: DW#347-12754.